|
🐜
|
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
62 auth.
F. Rivellese,
Anna E. A. Surace,
K. Goldmann,
E. Sciacca,
C. Çubuk,
G. Giorli,
C. John,
A. Nerviani,
L. Fossati-Jimack,
G. Thorborn,
Manzoor Ahmed,
E. Prediletto,
S. Church,
Briana M. Hudson,
S. Warren,
...
P. McKeigue,
F. Humby,
M. Bombardieri,
Michael R. Barnes,
Costantino Pitzalis,
F. Rivellese,
A. Nerviani,
L. Fossati-Jimack,
F. Humby,
P. Durez,
M. Buch,
H. Rizvi,
A. Mahto,
C. Montecucco,
B. Lauwerys,
N. Ng,
P. Ho,
V. Romão,
João Eurico Cabral da Fonseca,
P. Verschueren,
S. Kelly,
P. Sainaghi,
N. Gendi,
B. Dasgupta,
A. Cauli,
P. Reynolds,
J. Cañete,
J. Ramírez,
R. Celis,
R. Moots,
P. Taylor,
C. Edwards,
J. Isaacs,
P. Sasieni,
E. Choy,
C. Thompson,
S. Bugatti,
M. Bellan,
M. Congia,
C. Holroyd,
A. Pratt,
L. White,
Louise Warren,
Joanna Peel,
R. Hands,
G. Hadfield,
Costantino Pitzalis
|
7 |
2022 |
7
🐜
|
|
🐜
|
ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).
20 auth.
D. Sebag‐Montefiore,
R. Adams,
S. Gollins,
L. Samuel,
Rob Glynne-Jones,
R. Harte,
N. West,
P. Quirke,
A. Myint,
S. Bach,
...
P. Parsons,
S. Falk,
A. Dhadda,
V. Misra,
Nick Brown,
G. Brown,
M. Harrison,
L. White,
M. Duggan,
A. Lopes
|
3 |
2020 |
3
🐜
|
|
🐜
|
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
16 auth.
D. Propper,
Fangfei Gao,
M. Saunders,
D. Sarker,
J. Hartley,
V. Spanswick,
H. Lowe,
Louise D Hackett,
T. Ng,
P. Barber,
...
G. Weitsman,
S. Pearce,
L. White,
A. Lopes,
S. Forsyth,
D. Hochhauser
|
2 |
2022 |
2
🐜
|
|
🐢
|
922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
14 auth.
M. Forster,
R. Metcalf,
J. Sacco,
A. Kong,
G. Wheeler,
S. Forsyth,
R. Bhat,
K. Blair,
J. Ward,
H. Lowe,
...
V. Spanswick,
L. Ensell,
J. Hartley,
L. White
|
2 |
2020 |
2
🐢
|
|
🐜
|
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
20 auth.
Y. Wong,
P. Sankey,
D. Josephs,
Robert J. Jones,
S. Crabb,
S. Beare,
M. Duggan,
L. White,
N. Charlaftis,
G. Wheeler,
...
J. Linares,
S. Quezada,
L. Ensell,
C. Flanagan,
B. Kularatne,
Moon Chung,
C. Pritchard,
A. Freeman,
T. Marafioti,
M. Linch
|
2 |
2019 |
2
🐜
|
|
🐜
|
Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial
29 auth.
M. Linch,
Y. Wong,
Robert J. Jones,
P. Sankey,
D. Josephs,
S. Crabb,
J. Staffurth,
A. Zarkar,
L. White,
M. Duggan,
G. Pellizzari,
G. Wheeler,
S. Beare,
H. Cartwright,
J. Linares,
...
A. Akarca,
S. Quezada,
L. Ensell,
J. Hartley,
G. Attard,
Joanna C. Burr,
A. Jayaram,
B. Kularatne,
M. Kayani,
Moon Chung,
C. Pritchard,
A. Freeman,
A. Haider,
T. Marafioti
|
2 |
2021 |
2
🐜
|
|
🐢
|
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.
12 auth.
M. Forster,
J. Sacco,
A. Kong,
G. Wheeler,
S. Forsyth,
R. Bhat,
...
K. Blair,
H. Lowe,
V. Spanswick,
L. Ensell,
J. Hartley,
L. White
|
2 |
2019 |
2
🐢
|
